Press "Enter" to skip to content

Amneal cuts forecast as epinephrine shot supply issues linger, shares slump 36%

Shares of Amneal Pharmaceuticals Inc plunged 36% to an all-time low on Wednesday after the generic drugmaker cut its 2019 core earnings forecast due to supply uncertainties related to its epinephrine auto-injectors.

Original source:

Also Read:   Exclusive: Drugmakers from Pfizer to GSK to hike U.S. prices on over 200 drugs